Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias

PURPOSE: Incorporation of cytarabine into DNA activates checkpoint kinase 1 (Chk1), which stabilizes stalled replication forks, induces S-phase slowing, and diminishes cytarabine cytotoxicity. The selective Chk1 inhibitor SCH 900776 abrogates cytarabine-induced S-phase arrest and enhances cytarabine...

詳細記述

保存先:
書誌詳細
主要な著者: Karp, Judith E., Thomas, Brian M., Greer, Jacqueline M., Sorge, Christopher, Gore, Steven D., Pratz, Keith W., Smith, B. Douglas, Flatten, Karen S., Peterson, Kevin, Schneider, Paula, Mackey, Karen, Freshwater, Tomoko, Levis, Mark J., McDevitt, Michael A., Carraway, Hetty E., Gladstone, Douglas E., Showel, Margaret M., Loechner, Sabine, Parry, David A., Horowitz, Jo Ann, Isaacs, Randi, Kaufmann, Scott H.
フォーマット: Artigo
言語:Inglês
出版事項: 2012
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3596113/
https://ncbi.nlm.nih.gov/pubmed/23092873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-2442
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料